Prevalence of Human Papillomavirus Infection in Breast Cancer Cells from Thai Women

Breast cancer is the leading female cancer worldwide and is the most frequently diagnosed in Thai women. Its potential etiologic has not been clearly identified. Several recent reports could detect human papillomavirus (HPV) infection in breast cancer or benign breast lesions. HPV infection considered suggests being one of many risk factors for cancer development. The aim of this study was to determine the frequency of HPV infection in both breast cancer and benign breast lesion/tumor tissues. Seven hundred samples from Thai women were collected during 2013-2015 and statistically correlation between HPV infection, sociodemographic and histopathological parameters were also analyzed. HPV DNA detection and genotyping were performed by polymerase chain reaction and enzyme immunoassay, respectively. The results demonstrated that mean age of the patients were 41.76±12.53 years and 52.73±11.68 years for benign breast lesions/tumor and breast cancer samples, respectively. HPV DNA was detected in 25/700 (3.57%) samples, in which 10/350 (2.857%) from benign breast lesion/tumor samples and 15/350 (4.285%) from breast cancer samples. HPV 16 is the predominant types of this study, follow by HPV 33, 18, 35, 52. Most of HPV type detection samples belong to the high risk types, except 1/25 sample could be detected low risk type; HPV 6 which was presented as co-infection with the other high risk type. From sociodemographic and histopathological correlation analysis, all of studied parameters such as breast cancer history, hormone receptors status etc. did not show statistically significant correlated with HPV infection (P>0.05). In conclusion, the low frequency detection in this study suggests that HPV did not play the main important role for breast cancer development and represented highly controversial, but it may be causative agents of only a relative small proportion of all breast cancer or non-malignant breast lesion and it is the interesting data for further study in virus-associated cancer.

Comparison of Serum Lipid Profiles between Normal Controls and Breast Cancer Patients.

BACKGROUND: Researchers have reported association of plasma/serum lipids and lipoproteins with different cancers. Increase levels of circulating lipids and lipoproteins have been associated with breast cancer risk. AIM: THE AIM OF THIS STUDY IS TO COMPARE SERUM LIPID PROFILES: total-cholesterol (T-CHOL), triglyceride (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C) and very low density lipoprotein-cholesterol (VLDL-C) between breast cancer patients and normal participants. MATERIALS AND METHODS: A total of 403 women in this study were divided into two groups in the period during May 2006-April 2007. Blood samples were collected from 249 patients with early stage breast cancer and 154 normal controls for serum lipid profiles (T-CHOL, TG, HDL-C, LDL-C and VLDL-C) analysis using Hitachi 717 Autoanalyzer (Roche Diagnostic GmbH, Germany). TG, LDL-C and VLDL-C levels in breast cancer group were significantly increased as compared with normal controls group (P < 0.001), whereas HDL-C and T-CHOL levels were not. RESULTS: The results of this study suggest that increased serum lipid profiles may associate with breast cancer risk in Thai women. Further studies to group important factors including, cancer stages, types of cancer, parity, and menopausal status that may affect to lipid profiles in breast cancer patients along with an investigation of new lipid profiles to clarify most lipid factors that may involve in breast cancer development are needed.

Serum p53 antibodies in patients with lung cancer: correlation with clinicopathologic features and smoking.

Abnormalities of p53 gene can lead to the production of p53 antibodies (p53-Abs) in the serum of cancer patients. This study was designed to investigate the prevalence of p53-Abs in 133 lung cancer patients and the distribution of these antibodies to clinicopathologic features and smoking status. Twenty five (18.8%) lung cancer patients were found to have p53-Abs. The presence of p53-Abs did not correlate with sex or age but showed frequent association with tumors of squamous cell carcinoma (31%) in comparison with adenocarcinoma (13.6%) (P=0.052). There was a statistically significant difference in the incidence of p53-Abs between early disease group (stage I-II) and the advanced group (stage III-IV) (P=0.036), however, there was no relationship between the presence of p53-Abs and overall survival. Interestingly, the frequent of p53-Abs was higher in smokers (27.1%) than in non-smokers (13.6%), though the difference was of borderline of statistical significance (P=0.061). These findings suggested that p53-Abs could be a potential biomarker for the study of individual with lung cancer.